Arrhythmias & electrophysiology
Atrial Fibrillation Substrate and Catheter Ablation Outcomes in MYBPC3- and MYH7-Mediated Hypertrophic Cardiomyopathy
Authors' conclusion
Patients with MYBPC3- or MYH7-mediated HCM undergoing AF ablation have appreciably more low-amplitude LA signals, suggestive of fibrosis. However, catheter ablation remains an effective rhythm-control strategy.
Study context
- Population
- Patients with hypertrophic cardiomyopathy (HCM) who underwent genetic testing and catheter ablation for atrial fibrillation (AF)
- Participants
- 12 vs 15
- Exposure
- MYBPC3- or MYH7-mediated HCM vs gene-negative HCM undergoing AF catheter ablation
- Gene-positiven = 12
- Controln = 15reference
- Outcome
- LA normal voltage on electroanatomical mapping
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
| Group | Value | Intermediate scar (0.1-0.5 mV) | Dense scar (<0.1 mV) |
|---|---|---|---|
| Gene-positive | mean 87.7% (SD 5.03%) % of LA | 6.33% ± 1.97% | 5.93% ± 3.20% |
| Control | mean 94.3% (SD 3.58%) % of LA | 3.07% ± 2.46% | 2.61% ± 2.19% |
Value
Gene-positivemean 87.7% (SD 5.03%) % of LA
Controlmean 94.3% (SD 3.58%) % of LA
Intermediate scar (0.1-0.5 mV)
Gene-positive6.33% ± 1.97%
Control3.07% ± 2.46%
Dense scar (<0.1 mV)
Gene-positive5.93% ± 3.20%
Control2.61% ± 2.19%
- Gene-positive vs Control: P < 0.001 — normal voltage
- Gene-positive vs Control: P < 0.01 — intermediate scar
- Gene-positive vs Control: P < 0.01 — dense scar
Observational data: associations, not effects.
Further findings
Freedom from AF · 12 months
P = 0.92
Freedom from AF · 12 months
- Greater number of procedures required in the gene-positive cohort
Original publication
Atrial Fibrillation Substrate and Catheter Ablation Outcomes in MYBPC3- and MYH7-Mediated Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. Published 29 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →